Sobi gains commercial rights for Relistor®, Deflux® and Solesta® from PharmaSwiss

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the company has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor®, Deflux® and Solesta® in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia.

"I am delighted that we have expanded our successful partnership with PharmaSwiss and provide patients and physicians with additional treatment options that address unmet medical needs in each specific therapeutic category", said Alan Raffensperger, senior vice president and Chief Operating Officer at Sobi.

Sobi will handle all commercial activities in the territory including launch, market and patient access and promotion activities, while PharmaSwiss will be responsible for manufacturing, providing the finished products and products' information.

The three new products that Sobi will distribute, one pharmaceutical and two medical devices, are all approved for specialty care indications:

  • Relistor (methylnaltrexone bromide) is indicated for treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older
  • Deflux is indicated for treatment of children with vesicoureteral reflux
  • Solesta is indicated for the treatment of faecal incontinence in patients 18 years and older who have failed conservative therapy

 In June 2013, Sobi announced its first distribution agreement with PharmaSwiss to market the products Megace®, Monopril®, Cefzil® and Duricef® approved for the treatment of indications within the oncology, cardio-vascular and anti-infective therapy areas.

---

About Sobi Partner Products

Sobi Partner Products (SPP) is a business unit within Sobi that offers a unique commercial platform for partners with niche and specialty products. SPP provides extensive knowledge and local experience through our direct presence across EU, Eastern Europe, Russia, Middle East and North Africa. We apply an integrated commercial, medical and market access approach to products that address important unmet needs, spanning from named patient use (NPU) programmes, through to reimbursement and full commercialisation, primarily in the Centre of Expertise setting.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations Investor relations
Charlotte af Klercker, Corporate CommunicationsJörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 729 7327T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
charlotte.afklercker@remove-this.sobi.comjorgen.winroth@remove-this.sobi.com